217 related articles for article (PubMed ID: 9278616)
1. Bacterial filamentation of Yersinia pestis by beta-lactam antibiotics in experimentally infected mice.
Davis KJ; Vogel P; Fritz DL; Steele KE; Pitt ML; Welkos SL; Friedlander AM; Byrne WR
Arch Pathol Lab Med; 1997 Aug; 121(8):865-8. PubMed ID: 9278616
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Heine HS; Louie A; Sorgel F; Bassett J; Miller L; Sullivan LJ; Kinzig-Schippers M; Drusano GL
J Infect Dis; 2007 Sep; 196(5):782-7. PubMed ID: 17674322
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic susceptibilities of 94 isolates of Yersinia pestis to 24 antimicrobial agents.
Hernandez E; Girardet M; Ramisse F; Vidal D; Cavallo JD
J Antimicrob Chemother; 2003 Dec; 52(6):1029-31. PubMed ID: 14613959
[TBL] [Abstract][Full Text] [Related]
4. Laboratory studies on Yersinia pestis during the 1991 outbreak of plague in Lushoto, Tanzania.
Lyamuya EF; Nyanda P; Mohammedali H; Mhalu FS
J Trop Med Hyg; 1992 Oct; 95(5):335-8. PubMed ID: 1404556
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic treatment of experimental pneumonic plague in mice.
Byrne WR; Welkos SL; Pitt ML; Davis KJ; Brueckner RP; Ezzell JW; Nelson GO; Vaccaro JR; Battersby LC; Friedlander AM
Antimicrob Agents Chemother; 1998 Mar; 42(3):675-81. PubMed ID: 9517950
[TBL] [Abstract][Full Text] [Related]
6. Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops).
Davis KJ; Fritz DL; Pitt ML; Welkos SL; Worsham PL; Friedlander AM
Arch Pathol Lab Med; 1996 Feb; 120(2):156-63. PubMed ID: 8712895
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Heine HS; Louie A; Adamovicz JJ; Amemiya K; Fast RL; Miller L; Opal SM; Palardy J; Parejo NA; Sörgel F; Kinzig-Schippers M; Drusano GL
Antimicrob Agents Chemother; 2014 Jun; 58(6):3276-84. PubMed ID: 24687492
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.
Bonacorsi SP; Scavizzi MR; Guiyoule A; Amouroux JH; Carniel E
Antimicrob Agents Chemother; 1994 Mar; 38(3):481-6. PubMed ID: 8203841
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
Wendte JM; Ponnusamy D; Reiber D; Blair JL; Clinkenbeard KD
Antimicrob Agents Chemother; 2011 Aug; 55(8):3752-7. PubMed ID: 21628541
[TBL] [Abstract][Full Text] [Related]
10. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
[TBL] [Abstract][Full Text] [Related]
11. [Sensitivity of Yersinia pestis to antibiotics: 277 strains isolated in Madagascar between 1926 and 1989].
Rasoamanana B; Coulanges P; Michel P; Rasolofonirina N
Arch Inst Pasteur Madagascar; 1989; 56(1):37-53. PubMed ID: 2633713
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional profiling of a mice plague model: insights into interaction between Yersinia pestis and its host.
Liu H; Wang H; Qiu J; Wang X; Guo Z; Qiu Y; Zhou D; Han Y; Du Z; Li C; Song Y; Yang R
J Basic Microbiol; 2009 Feb; 49(1):92-9. PubMed ID: 18759226
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
14. Activation of Heme Oxygenase Expression by Cobalt Protoporphyrin Treatment Prevents Pneumonic Plague Caused by Inhalation of
Willix JL; Stockton JL; Olson RM; Anderson PE; Anderson DM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015027
[TBL] [Abstract][Full Text] [Related]
15. Yersinia pestis: still a plague in the 21st century.
Josko D
Clin Lab Sci; 2004; 17(1):25-9. PubMed ID: 15011977
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
[TBL] [Abstract][Full Text] [Related]
17. [Antibiotic sensitivity of strains of the plague microbe isolated from foci in the Caucasus and Transcaucasia].
Tarasova VE; Eremitskaia GN; Proskurina VA
Antibiotiki; 1981 May; 26(5):365-7. PubMed ID: 7259143
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92.
Agar SL; Sha J; Foltz SM; Erova TE; Walberg KG; Baze WB; Suarez G; Peterson JW; Chopra AK
Microbes Infect; 2009 Feb; 11(2):205-14. PubMed ID: 19073275
[TBL] [Abstract][Full Text] [Related]
19. Experimental infection of ground squirrels (Citellus pygmaeus Pallas) with Yersinia pestis during hibernation.
Bizanov G; Dobrokhotova ND
J Infect; 2007 Feb; 54(2):198-203. PubMed ID: 16580730
[TBL] [Abstract][Full Text] [Related]
20. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Louie A; Heine HS; VanScoy B; Eichas A; Files K; Fikes S; Brown DL; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
Antimicrob Agents Chemother; 2011 Feb; 55(2):822-30. PubMed ID: 21115791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
